BIA Networking Lunch - Stevenage


Registration has now closed. If you wish to join the waiting list, please contact

The BIA will be running another popular networking lunch, hosted by Stevenage Bioscience Catalyst. This is a great opportunity to hear from local members, meet new business contacts and grab a bite to eat. We are excited to be showcasing members the Stevenage region

We are pleased to announce that the Office for Life Sciences (OLS) will also be joining us for a special Brexit-focused session. 


12.00:  Lunch and networking

13.00:  Steve Bates, CEO, BIA 

13.10:  Sally Ann Forsyth, CEO, Stevenage Bioscience Catalyst 

13.20:  Company presentations
Representatives from Freeline Therapeutics, LifeArc, and LifT Biosciences will join us to give short presentations on their work and recent developments.

14.00:  Networking  - tea, coffee, and biscuits provided

14.25:  OLS Brexit preparedness workshop
The Office for Life Sciences (OLS) will be holding a workshop to help inform and update member companies prepare for EU Exit.

OLS will deliver presentations on the following areas: Introduction to the Office for Life Sciences; Regulations update; Continuity of Supply; Trader readiness; Workforce; and Q&A.

15:15  Close



Steve Bates

Chief Executive Officer


Steve Bates has been the CEO of the UK Bioindustry Association since 2012. He currently chairs the International Council of Biotech Associations and has been a Board member of Europabio since 2015. Steve is the visible face of the vibrant UK life sciences industry to government and media. He sits on the UK’s Life Sciences Council and Life Sciences Industrial Strategy Implementation Board. Steve has championed with government effective industrial incentives like the Biomedical Cataylst which have crowded-in private sector investment into UK SMES. He has forged links for the sector across the USA, Europe and in China. In his time at the BIA Steve has developed new member groups focused on cell and gene therapy, genomics and engineered biology. A strong advocate of partnership working, Steve champions sector collaboration with research charities and academia. Proud to lead an organisation with a diverse Board with over 40% female representation, Steve is committed to next generation talent and developing the skills needed for the sector to flourish. Before the BIA, Steve worked for Genzyme and as an advisor to the UK Government of Tony Blair. He was made OBE for services to innovation in 2017.

Dr Sally Ann Forsyth

Chief Executive Officer

Stevenage Bioscience Catalyst

Sally Ann has been responsible for the strategy, growth and development of 4 internationally recognised science parks including Harwell Oxford (STFC), Colworth Science Park (Unilever), Norwich Research Park (BBSRC) and most recently Stevenage Bioscience Catalyst (GSK/Wellcome). She began her career with Unilever as part of the management training scheme and later had lead responsibility for In-Licensing, Strategic Alliances and Open Innovation within the Unilever Foods and Discovery divisions. Being part of the founding team of Unilever Ventures and Unilever Technology Ventures gave Sally Ann an insight into the needs of growing companies. She gained her property experience through Goodman International where she was Director of Science Parks responsible for the development and management of their UK portfolio.

Sally Ann is passionate about the translation of UK science into world leading innovations and the creation of supportive environments to help early stage companies grow. She has a PhD in molecular biology from the University of Cambridge and is a qualified management accountant (CGMA).

Jane Whitrow

Vice President, Business Operations

Freeline Therapeutics

Jane is a Chartered Accountant who brings specialist experience of working with small and medium-sized technology businesses.

She joined Freeline after seven years at IXICO, where she was responsible for fundraising, forecasting, financial reporting, investor relations, HR, IT, legal, facilities, Quality and Company Secretarial. Here she was part of the management team that acquired Phytopharm, and the subsequent listing on the AIM market. Before that, she worked for a variety of high-tech and start-up companies, including Cambridge Biostability, Novacta Biosystems and BioSyntha.

Jane also spent five years at the biotech venture capitalist Merlin Ventures (latterly Merlin BioSciences), becoming Finance Director. She trained as an accountant with KPMG focusing on small and medium-sized technology businesses. Jane has a BSc from the University of Manchester and a PhD in Plant Genetics from the University of Birmingham

Justin Bryans

Executive Director, Drug Discovery


Justin trained at the Universities of York and Oxford and has worked as a medicinal chemist for over 25 years in Biotech and Pharma, including Parke-Davis and Pfizer, delivering a number of clinical candidates. He joined LifeArc in 2005 where he currently leads the drug discovery team collaborating with academics on cutting edge science to deliver proof of concept and develop potential drugs for diseases of high unmet need. Justin teaches on drug discovery at QMUL, UCL and the Wellcome Trust. He also sits on the Drug Discovery Committee for Cancer Research UK and is a Fellow of the Royal Society of Chemistry.

Harry Kwong

QC & Process Development Engineer

LIfT BioSciences

Harry joined LIfT BioSciences in 2019 where he is responsible for the manufacturing strategies that support the early stage development and production of the company’s product, N-LIfT. His areas of focus include process development and optimisation as well as scale up and tech transfer with a vision of delivering N-LIfT to the market. Harry received a BSc in Biochemistry from Imperial College London and completed a master’s in Biochemical Engineering at UCL.

LIfT Biosciences is a Biotech bringing to market a 1st in class allogeneic innate cell therapy called Neutrophil Only Leukocyte Infusion Therapy (N-LIfT). N-LIfT has the game-changing potential to destroy all solid tumours irrespective of mutation or strain. N-LIfT uses a special type of N1a neutrophil with superior cancer killing and immune recruitment capabilities. Our vision is to develop the world’s first cell bank of mass produced ‘cancer killing neutrophils’ to deliver a portfolio of immuno-oncology cell therapies for delivering complete remission in all solid tumours, with an initial focus on high unmet need orphan tumours such as those found in the lung, liver and pancreas.

Anusha Panjwani

Senior Policy and Engagement Manager

Office for Life Sciences

David Griffiths-Johnson

Head of Investment and Engagement

Office for Life Sciences

Alex Mulchrone

Senior Policy Advisor

Office for Life Sciences



Stevenage Bioscience Catalyst
Gunnels Wood Rd


Free for members and non-members

By registering to this event you accept our Terms & Conditions

Thank you to our event host


BIA Annual Supporters